Kite Pharma
在场
是其中之一......
- Forbes Global 2000 (#575);
- Fortune 500 (#154);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Gilead Sciences 是一家在股票代码 GILD (US) 下上市的公司。
Gilead Sciences 在 7 个国家有直接业务。Gilead Sciences 拥有 7家子公司，其中包括 Gilead Sciences Canada、Gilead Sciences EMEA 和 Gilead Sciences Germany。
他们在：
涉及Gilead Sciences的并购和融资。
- Gilead Sciences has announced the acquisition of CymaBay Therapeutics (公布2024二月15号).
高管
查看带有其 19 名主要高管的组织结构图
Kite Pharma 搜索最多的简介
- Cindy Perettie, Chief Executive Officer
- Chris McDonald, Vice President of Technical
- Warner Biddle, Senior Vice President & Global Head of Commercial
高管在Kite Pharma变化
- Dick Sundh 曾任 Head of Australia, Canada and Europe, 现任 Interim Head of Global Commercial (新闻发布的2024十月1号).
高管在Gilead Sciences变化
- Merdad Parsey, Chief Medical Officer, 将于 20251月 退休 (新闻发布的2024七月18号).
创建提醒
跟踪 Kite Pharma 的高管变动
健康
Gilead Sciences 拥有 1,966 家竞争者，其中包括 Siemens Healthineers (德国)、IQVIA (美国(美洲)) 和 Nestlé Health Science (瑞士)。
Popular M&A news in 健康
- Radon Medical Imaging 已收购 Alpha Imaging (公布2024十一月20号).
- TowerBrook Capital Partners 已收购 R1 RCM (公布2024十一月19号).
- Kewaunee Scientific 已收购 Nu Aire (公布2024十一月6号).
健康 行业的其他推荐联系人
消息
Kite Pharma 的最新新闻稿
- Gileads Livdelzi Seladelpar Demonstrated a Sustained Efficacy and Long Term Safety Profile in Management of Primary Biliary Cholangitis
- Gilead Presents Full PURPOSE 2 Data Results for Twice Yearly Lenacapavir for HIV Prevention at HIV Glasgow
- Gilead Prices 3.5 Billion of Senior Unsecured Notes
- Kite to Highlight Industry Leading CAR T Cell Therapy Portfolio at ASH 2024 Including Positive Survival Outcomes in Both Clinical Trials and the Real World
- Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
- Gilead Sciences to Present at Upcoming Investor Engagements
- Gilead Sciences Announces Third Quarter 2024 Financial Results
- Late Breaking Clinical Data and Real World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
- Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease AASLD Meeting 2024
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
- View more press releases Close
关于 Kite Pharma 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Cindy Perettie 
